Effect of Saffron on Depression due to Multiple Sclerosis

The effect of Saffron on depression, resilience, and quality of life in patients with Multiple Sclerosis (MS)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251102067860N1

Enrollment

Registered

2025-11-23

Start date

2026-06-22

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Depression. Condition 2: Multiple sclerosis. Other depressive episodes Multiple sclerosis

Interventions

Intervention 1: Intervention group: They will take one standardized saffron tablet containing 15 mg of crocin (Crocinna tablet from Samisaz Company) daily after breakfast. Intervention 2: Control grou

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diagnosis of MS by a neurologist (based on McDonald 2017 criteria) Age 18-60 years Diagnosis of depression by a psychiatrist No change in MS medication dosage in the past 3 months

Exclusion criteria

Exclusion criteria: Patient dissatisfaction

Design outcomes

Primary

Measure	Time frame
Depression score. Timepoint: Base, Week 4, Week 8. Method of measurement: Hamilton Questionnaire.;Resilience score. Timepoint: Base, Week 4, Week 8. Method of measurement: CD-RISC Questionnaire.;Quality of life score. Timepoint: Base, Week 4, Week 8. Method of measurement: MSQOL-54 Questionnaire.	—

Secondary

Measure	Time frame
Side effects. Timepoint: Weeks 4 and 8. Method of measurement: Toll registration questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZaneera Salimi

Mashhad University of Medical Sciences

SalimiZN@mums.ac.ir+98 51 3700 2206

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026